Delcath Systems, Inc.

451 articles about Delcath Systems, Inc.

• Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update

  11/13/2023

  Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023.

• Delcath Systems to Host Third Quarter 2023 Results Call

  11/6/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.  

• Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers

  10/16/2023

  Delcath Systems, Inc. (Nasdaq: DCTH) today announced the publication of an article entitled "Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study" in the peer reviewed oncology journal Cancers.

• Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference

  10/10/2023

  Delcath Systems, Inc. announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.

• Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023

  10/3/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the Roth MKM Healthcare Opportunities Conference in New York. Delcath CEO, Gerard Michel will present on October 12 at 11:45 AM ET.

• Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 27, 2023

  9/27/2023

  Delcath Systems, Inc. announces that the Company granted equity awards, in the form of a total of 86,000 shares of the Company's common stock, outside of the Company's Omnibus 2020 Equity Incentive Plan as amended, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.

• A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

  9/11/2023

  Delcath Systems, Inc. (Nasdaq: DCTH) today announced the details of an oral presentation by independent investigators on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting held in Copenhagen, Denmark.

• Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023

  9/5/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference.

• Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

  9/1/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the Tranche A warrants issued as part the previously announced March 29, 2023 Private Investment in Public Equity (PIPE) financing.

• Delcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

  8/29/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an oral presentation by independent investigators at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting to be held in Copenhagen, Denmark from September 9-13, 2023.

• 

  Week in Review: Obesity Drug Race, Ipsen Therapy Finally Gets Approval and More

  8/18/2023

  Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
• 

  Delcath Gets FDA Approval for Cancer Drug-Device Combo 10 Years After Rejection

  8/16/2023

  Following a nearly decade-long effort, Delcath Systems finally won the FDA’s greenlight for its Hepzato Kit for the liver-directed treatment of adult patients with metastatic uveal melanoma.

• Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

  8/14/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration (FDA) approved HEPZATO KIT.

• Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

  8/9/2023

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported business highlights and financial results for the second quarter ended June 30, 2023.

• Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 21, 2023

  6/21/2023

  Delcath Systems, Inc. announces that the Company granted equity awards, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment for two individuals, the Chief Medical Officer, Vojislav Vukovic, and the Principal Accounting Officer and Principal Financial Officer, Sandra Pennell.

• Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance

  6/7/2023

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance.

• Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results

  5/12/2023

  Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023.

• Delcath Systems to Participate in the Lytham Partners Spring 2023 Investor Conference

  5/9/2023

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.

• Delcath Systems to Host First Quarter 2023 Results

  5/3/2023

  Delcath Systems, Inc. (Nasdaq: DCTH) announced today it will host a conference call on May 12, 2023, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023.  

• Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility

  4/3/2023

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it reached an agreement to amend its existing loan agreement with Avenue Venture Opportunities Fund, L.P..